Using A Dual-Target TCE Strategy to Eliminate BCMA+ & CD19+ Pathogenic Cells
Time: 4:00 pm
day: Day One
Details:
- Presenting the scientific basis and emerging literature supporting the depletion of both plasma cells and memory B cells to achieve more complete and lasting immunomodulation.
- Understanding which B cell subsets drive pathology and how to measure depletion effectiveness
- Leveraging Preclinical & Translational Models to Evaluate Safety and Predict Toxicity Risks – Discussing the tools and models Aditum Bio is using to anticipate cytokine release, on-target off-tissue effects, and other safety challenges associated with dual B cell targeting TCEs.
